Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 103-110

  Vescio, R A ^a,b,c   Han, E J ^a   Schiller, G J ^a,b   Lee, J C ^a   Wu, C H ^a   Cao, J ^a   Shin, J ^a   Kim, A ^a   Lichtenstein, A K ^a,b   Berenson, J R ^a,b  

^a Division of Hematology Oncology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Pediatric Hematology/Oncology   (United States)

Author keywords

Bone marrow transplantation; Minimal residual disease; Peripheral stem cell transplantation; Quantitative PCR; V(H)

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTAMINATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; LEUKAPHERESIS; MULTIPLE MYELOMA; MYELOMA CELL; OLIGONUCLEOTIDE PROBE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; AGED; BONE MARROW; BONE MARROW EXAMINATION; BONE MARROW PURGING; DNA, NEOPLASM; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENES, IMMUNOGLOBULIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKAPHERESIS; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM CIRCULATING CELLS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, AUTOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 9544246742     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Vescio RA, Lichtenstein AK, Berenson JR. Myeloma, macroglobulinemia, and heavy chain disease. In: Haskell CM (ed). Cancer Treatment (Fourth Edn). WB Saunders: Philadelphia, 1995, pp 1094-1115.
2. Cavo M, Galieni P, Zuffa E et al. Prognostic variables and clinical staging in multiple myeloma factors and survival in multiple myeloma. Blood 1989; 74: 1774-1780.
3. Alexanian R, Haut A, Khan A et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
4. Bladé J, López-Guillermo A, Bosch F et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 1994; 88: 117-121.
5. Boccadoro M, Pileri A. Standard chemotherapy for myelomatosis: an area of great controversy. Hematol Oncol Clin N Am 1992; 6: 371-382.
6. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-342.
7. Kyle RA. Newer approaches to the management of multiple myeloma. Cancer 1993; 72: 3489-3494.
8. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. New Engl J Med 1994; 330: 484-489.
9. Gahrton G, Tura S, Ljungman P et al. Allogeneic bone marrow transplantation in multiple myeloma. New Engl J Med 1991; 325: 1267-1272.
10. Bensinger WI, Buckner CD, Clift RA et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10: 1492-1497.
11. Reece DE, Shepherd JD, Klingemann H-G et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 117-123.
12. Fermand J-P, Shevret S, Ravaud P et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82: 2005-2009.
13. Vesole DH, Jagannath S, Glenn L, Barlogie B. Autotransplantation in multiple myeloma. Hematol Oncol Clin N Am 1993; 7: 613-630.
14. McElwain TJ, Selby PJ, Gore ME et al. High-dose chemotherapy and autologous bone marrow transplantation for myeloma. Eur J Haematol 1989; 43: 152-156.
15. Schiller GJ, Nimer S, Vescio R et al. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. Bone Marrow Transplant 1994; 14: 131-136.
16. Barlogie B, Gahrton G. Bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1991; 7: 71-79.
17. Anderson KC, Barut BA, Ritz J et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 1991; 77: 712-720.
18. Gobbi M, Cavo M, Tazzari PL et al. Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. Eur J Haematol 1989; 43 (Suppl. 51): 176-181.
19. Reece DE, Barnett MJ, Connors JM et al. Treatment of multiple myeloma with intensive chemoradiotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 1993; 11: 139-146.
20. Rhodes EGH, Baker PK, Duguid JKM et al. A method for clinical purging of myeloma bone marrow using peanut agglutinin as an anti-plasma cell agent, in combination with CD19 monoclonal antibody. Bone Marrow Transplant 1992; 10: 485-489.
21. Shimazaki C, Wisniewski D, Scheinberg DA et al. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads. Blood 1988; 72: 1248-1254.
22. Tong AW, Lee JC, Fay JW, Stone MJ. Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complement. Blood 1987; 70: 1482-1489.
23. Schiller G, Vescio R, Freytes C et al. Transplantation of CD34-positive peripheral blood progenitor cells following high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-397.
24. International Bone Marrow Transplant Registry Newsletter, 7/1995.
25. Langenmayer I, Weaver C, Buckner CD et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15: 241-246.
26. Billadeau D, Quam L, Thomas W et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818-1824.
27. Carradini P, Voena C, Omedé P et al. Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 1993; 7: 1879-1882.
28. Van Riet I, Heirman C, Lacor P et al. Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol 1989; 73: 289-295.
29. Rowley SD, Jones RJ, Piantadosi S et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74: 501-506.
30. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
31. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
32. + stem cells using RT-PCR on whole cells. PCR Meth Applic 1994; 3: 278-284.
33. Vescio RA, Cao J, Hong CH et al. Myeloma Ig heavy chain variable region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 1995; 155: 2487-2497.
34. Bakkus MH, Heirman C, Van Riet I et al. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326-2335.
35. Ralph QM, Brisco MJ, Joshua DE et al. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. Blood 1993; 82: 202-206.
36. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
37. Vescio RA, Hong CH, Cao J et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84: 3283-3290.
38. Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 1992; 29: 192-203.
39. D'Aquila RT, Bechtel LJ, Videler JA et al. Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucleic Acids Res 1991; 19: 3749.
40. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1982, pp E.3-E.4.
41. Tomlinson IM, Walter G, Marks JD et al. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 1992; 227: 776-798.
42. Kabat EA, Wu TT, Reid-Miller M et al. Sequence of Proteins of Immunological Interest. National Institutes of Health: Bethesda, 1987.
43. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
44. Shpall EJ, Jones RB, Franklin W et al. CD34 positive (+) marrow and/or peripheral blood progenitor cells (PBPCs) provide effective hematopoietic reconstitution of breast cancer patients following high-dose chemotherapy with autologous hematopoietic progenitor cell support. Blood 1992; 80 (Suppl. 1): 24a (Abstr 88).
45. Attal M, Harousseau JL, Stoppa AM et al. High-dose therapy in multiple myeloma: a prospective randomized study of the Intergroupe Français Du Myelome (IFM). Blood 1994; 84 (Suppl. 1): 386a (Abstr 1530).
46. Selby PJ, McElwain TJ, Nandi AC et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55-62.
47. Harousseau JL, Milpied N, Laporte JP et al. Double-intensive therapy in high-rise multiple myeloma. Blood 1992; 79: 2827-2833.
48. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
49. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-3057.
50. Bird JM, Bloxham D, Samson D et al. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 1994; 88: 110-116.
51. Mariette X, Fermand JP, Brouet JC. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 1994; 14: 47-50.
52. Corradini P, Voena C, Astolfi M et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596-1602.
53. Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cm sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 1993; 178: 1091-1096.
54. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178: 1023-1031.
55. Bakkus MH, Van Riet I, Van Camp B, Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B-cell. Br J Haematol 1994; 87: 68-74.
56. de la Rubia J, Bonanad S, Palau J et al. Rapid progression of multiple myeloma following G-CSF mobilization. Bone Marrow Transplant 1994; 14: 475-476.
57. Zhang X-G, Bataille R, Jourdan M et al. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76: 2599-2605.
58. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma Hematol Oncol Clin N Am 1992; 6: 297-322.
59. Gazitt Y, Reading C, Lee JH et al. Differential peripheral blood mobilization of tumor and normal hematopoietic progenitor cells (HPC) in multiple myeloma (MM). Blood 1994; 84 (Suppl. 1): 354a.